Literature DB >> 28329345

Prevalence and Clinical Correlates of Sarcopenia, Identified According to the EWGSOP Definition and Diagnostic Algorithm, in Hospitalized Older People: The GLISTEN Study.

Lara Bianchi1, Pasquale Abete2, Giuseppe Bellelli3,4, Mario Bo5, Antonio Cherubini6, Francesco Corica7, Mauro Di Bari8,9, Marcello Maggio10, Giovanna Maria Manca11, Maria Rosaria Rizzo12, Andrea P Rossi13, Francesco Landi14, Stefano Volpato1,15.   

Abstract

BACKGROUND: Prevalence of sarcopenia is substantial in most geriatrics settings, but estimates vary greatly across studies because of difference in population characteristics, diagnostic criteria, and methods used to assess muscle mass, muscle strength, and physical performance. We investigated the feasibility of the European Working Group on Sarcopenia in Older People (EWGSOP) algorithm assessment in hospitalized older adults and analyzed prevalence and clinical correlates of sarcopenia.
METHODS: Cross-sectional analysis of 655 participants enrolled in a multicenter observational study of older adults admitted to 12 acute hospital wards in Italy. Sarcopenia was assessed as low skeletal mass index (kg/m2) plus either low handgrip strength or low walking speed (EWGSOP criteria). Skeletal muscle mass was estimated using bioimpedance analysis.
RESULTS: Of the 655 patients (age 81.0 ± 6.8 years; women 51.9%) enrolled in the study, 275 (40.2%) were not able to perform the 4-m walking test because of medical problems. The overall prevalence of sarcopenia on hospital admission was 34.7% (95% confidence interval 28-37) and it steeply increased with aging (p < .001). In multivariable analysis, patients with sarcopenia on hospital admission were older and were more likely to be male and to have congestive heart failure, cerebrovascular disease, and severe basic activities of daily living disability. The prevalence of sarcopenia was inversely correlated with body mass index.
CONCLUSION: Based on EWGSOP criteria, prevalence of sarcopenia is extremely high among older adults on admission to acute hospital wards. Older age, male gender, congestive heart failure, cerebrovascular disease, severe activities of daily living disability, and body mass index were the clinical variables significantly associated with the presence of sarcopenia.
© The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Acute care; Hospital; Prevalence; Sarcopenia

Mesh:

Year:  2017        PMID: 28329345     DOI: 10.1093/gerona/glw343

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  37 in total

1.  International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.

Authors:  E Dent; J E Morley; A J Cruz-Jentoft; H Arai; S B Kritchevsky; J Guralnik; J M Bauer; M Pahor; B C Clark; M Cesari; J Ruiz; C C Sieber; M Aubertin-Leheudre; D L Waters; R Visvanathan; F Landi; D T Villareal; R Fielding; C W Won; O Theou; F C Martin; B Dong; J Woo; L Flicker; L Ferrucci; R A Merchant; L Cao; T Cederholm; S M L Ribeiro; L Rodríguez-Mañas; S D Anker; J Lundy; L M Gutiérrez Robledo; I Bautmans; I Aprahamian; J M G A Schols; M Izquierdo; B Vellas
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

2.  The Association between Sarcopenia and Prealbumin Levels among Elderly Chinese Inpatients.

Authors:  Q Chen; Q Hao; Y Ding; B Dong
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

3.  Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review.

Authors:  Behrang Amini; Sean P Boyle; Robert D Boutin; Leon Lenchik
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-09-15       Impact factor: 6.053

4.  CT Attenuation and Cross-Sectional Area of the Pectoralis Are Associated With Clinical Characteristics in Chronic Obstructive Pulmonary Disease Patients.

Authors:  Xin Qiao; Gang Hou; Jian Kang; Qiu-Yue Wang; Yan Yin
Journal:  Front Physiol       Date:  2022-06-03       Impact factor: 4.755

5.  Development of Formulas for Calculating L3 Skeletal Muscle Mass Index and Visceral Fat Area Based on Anthropometric Parameters.

Authors:  Wei Ji; XiangLiang Liu; Yiqun Zhang; Yixin Zhao; YuWei He; JiuWei Cui; Wei Li
Journal:  Front Nutr       Date:  2022-06-17

6.  Diagnosis of Sarcopenia in Long-Term Care Homes for the Elderly: the Sensitivity and Specificity of Two Simplified Algorithms with Respect to the EWGSOP Consensus.

Authors:  A I Rodriguez-Rejon; R Artacho; A Puerta; A Zuñiga; M D Ruiz-Lopez
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

7.  Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis.

Authors:  S K Papadopoulou; P Tsintavis; P Potsaki; D Papandreou
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

8.  Frailty Related Factors as Predictors of Functional Recovery in Geriatric Rehabilitation: The Sarcopenia And Function in Aging Rehabilitation (SAFARI) Multi-Centric study.

Authors:  A Calle; G Onder; A Morandi; G Bellelli; E Ortolani; L M Pérez; M Mesas; A Sanniti; P Mazzanti; C N Platto; S Gentile; N Martinez; M Roquè; M Inzitari
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

9.  Handgrip strength as a valid practical tool to screen early-onset sarcopenia in acute care wards: a first evaluation.

Authors:  Marie Blanquet; Guillaume Ducher; Anaïs Sauvage; Sylvain Dadet; Vincent Guiyedi; Nicolas Farigon; Candy Guiguet-Auclair; Pauline Berland; Jérôme Bohatier; Yves Boirie; Laurent Gerbaud
Journal:  Eur J Clin Nutr       Date:  2021-04-13       Impact factor: 4.016

10.  Prognostic value of a rapid sarcopenia measure in acutely ill older adults.

Authors:  Márlon J R Aliberti; Claudia Szlejf; Kenneth E Covinsky; Sei J Lee; Wilson Jacob-Filho; Claudia K Suemoto
Journal:  Clin Nutr       Date:  2019-08-31       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.